FCX-007 / Precigen, Paragon Biosci  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FCX-007 / Precigen, Paragon Biosci
RDEB, NCT02810951: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Terminated
1/2
6
US
FCX-007, Genetically-Modified Autologous Human Dermal Fibroblasts
Castle Creek Biosciences, LLC.
Epidermolysis Bullosa Dystrophica, Recessive
09/20
04/22

Download Options